Post

Takeda signs option agreement with Ascentage for CML drug

Pharma giant Takeda has signed an option agreement with Ascentage Pharma to enter into an exclusive licence agreement for olverembatinib …

Pre-diabetes rates increase amidst a renaissance for type 2 diabetes research

England’s National Health Service (NHS) has reported an 18% increase in the number of people with non-diabetic hyperglycaemia – also …

Santa Ana Bio secures $168m for inflammatory disease treatments

Precision immunology company Santa Ana Bio has announced a substantial funding injection of $168m through Series A and B financing …

Suven Pharmaceuticals to gain controlling stake in Sapala Organics

India-based Suven Pharmaceuticals has announced a definitive agreement to acquire a strategic controlling stake in Sapala Organics. The acquisition marks a …

AbbVie and FutureGen link on inflammatory bowel disease

AbbVie has made a licence agreement with FutureGen Biopharmaceutical to develop a next-generation therapy, FG-M701, for inflammatory bowel disease (IBD). The …